INKT MiNK Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 10 May 2022 MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report

   • Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022
   • GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr
   • BCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022
   • Ended First Quarter with $34.7M in cash with a projected 2022 cash burn of $16.8M

   NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the first quarter 2022 and provided a corporate business update.

   "MiNK has made important progress in advancing…

   View Full Article
2. 27 April 2022 MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update

   NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its first quarter 2022 financial results and business update before the market opens on Tuesday, May 10, 2022.
   

   The financial report and an update on business progress will be released through a press release on online distribution networks and available on the investor section of the company's website.

   About MiNK Therapeutics
   MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery…

   View Full Article
3. 18 March 2022 MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

   • AgenT-797 (Allo-iNKTs) +/- anti-PD-1 clinical trial underway in solid tumor cancers
     
   • Benefit in severe COVID-19 ARDS shows 75% survival rate in patients treated with Allo-iNKTs
   • AgenT-797 treatment with no lymphodepletion shows no cytokine release syndrome or neurotoxicity
   • 2021 annualized cash burn is ~ $13M

   NEW YORK, March 18, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, reported financial results for the fourth quarter and full year 2021.

   "We have advanced our allo-iNKT program with multiple…

   View Full Article
4. 03 March 2022 MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update

   NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its independent fourth quarter and full year 2021 financial results and a business update before the market opens on Friday, March 18, 2022.
   

   The financial report and an update on business progress will be released through a press release and online distribution networks and available on the investor section of the company's website.

   About MiNK Therapeutics
   MiNK Therapeutics is a clinical-stage biopharmaceutical company…

   View Full Article
5. 03 March 2022 MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers

   • Clinical data show AgenT-797 can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity
   • Clinical trials underway in solid tumor cancers, multiple myeloma, and viral ARDS

   NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that it has begun dosing patients with solid tumor cancers with AgenT-797 alone and in combination with approved anti-PD-1 checkpoint inhibitors in a Phase 1 open-label clinical trial.
   

   "This is the first study…

   View Full Article